Please login to the form below

Not currently logged in
Email:
Password:

Czech biotech Sotio selects Chiltern International

UK CRO will work on late-stage trials for its prostate cancer therapy

UK headquartered contract research organisation (CRO) Chiltern International has been appointed by Czech biotech Sotio to carry out phase III clinical trials.

Under the agreement, the CRO will provide full-service management of the phase III trials, entitled Viable, which will involve 126 treatments for 750 prostate cancer patients from across Europe.

The trials will assist the biotech company's development of Active Cellular Immunotherapy (ACI), which focuses on cancer and autoimmune disease treatments - specifically, therapies using an immunotherapy platform based activated dendritic cells.

Chiltern will also be responsible for processing the data obtained during the clinical evaluation.

"I am very pleased that we have been selected to manage this high profile trial," said Chiltern CEO Dr Jim Esinhart.

"I believe it underscores the strengths and expertise of our global oncology therapeutic area team. We look forward to working in close partnership with Sotio deliver a quality outcome."

Viable will be a global clinical trial, tracking a total of 1,170 prostate cancer patients from Europe and the US.

19th March 2013

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

ASH 2022: bad blood but big advances
Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...